Ratings by UBS (Michael Leuchten)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/11/2025 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2022 | GlaxoSmithKline | GSK | Downgrade | Sell (Neutral) |
33.47 (51.96) |
55.24% | Details | |
| 4/14/2021 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details |
